1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Growth of the French market is expected to be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies such as MGN-1703, a maintenance therapy for first-line patients responding to chemotherapy with or without biological agents. Germany has shifted towards a strict reference pricing system and has begun implementing price cuts, indicating that pharmaceutical companies can no longer count on the free pricing schemes previously in place in the German market. GlobalData believes that the government is likely to make similar moves in the future. As in the 5EU in general, cost effectiveness is a major priority for the Italian government and will be a major limitation on the pricing and uptake of new drugs during the forecast period. The Spanish government has been forced to institute severe cost-control measures due to economic policies stemming from the 2008 financial crisis. Growth in the UK is expected to be restricted by the NHS reimbursement watchdog, NICE. At present, no branded treatments have been given approval from NICE in the UK.

Scope

- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU CRC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table Of Contents

PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 18
3.2 Clinical Staging 19
3.3 Symptoms 20
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Screening and Diagnosis 22
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 25
4.1.3 Clinical Practice 29
4.2 France 34
4.2.1 Screening and Diagnosis 36
4.2.2 Clinical Practice 36
4.3 Germany 38
4.3.1 Screening and Diagnosis 40
4.3.2 Clinical Practice 40
4.4 Italy 42
4.4.1 Screening and Diagnosis 44
4.4.2 Clinical Practice 44
4.5 Spain 46
4.5.1 Screening and Diagnosis 48
4.5.2 Clinical Practice 48
4.6 UK 50
4.6.1 Screening and Diagnosis 52
4.6.2 Clinical Practice 52
5 Competitive Assessment 55
5.1 Overview 55
5.2 Product Profiles — Major Brands 56
5.2.1 Avastin (Bevacizumab) 56
5.2.2 Erbitux (Cetuximab) 61
5.2.3 Vectibix (Panitumumab) 65
5.2.4 Stivarga (Regorafenib) 68
5.2.5 Zaltrap (Ziv-Aflibrcept) 72
5.2.6 Lonsurf (TAS-102) 76
5.2.7 Xeloda (Capecitabine) 80
6 Unmet Need and Opportunity 84
6.1 Overview 84
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 85
6.2.1 Unmet Need 85
6.2.2 Gap Analysis 87
6.2.3 Opportunity 87
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 89
6.3.1 Unmet Need 89
6.3.2 Gap Analysis 90
6.3.3 Opportunity 90
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 91
6.4.1 Unmet Need 91
6.4.2 Gap Analysis 92
6.4.3 Opportunity 92
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 93
6.5.1 Unmet Need 93
6.5.2 Gap Analysis 93
6.5.3 Opportunity 94
7 Pipeline Assessment 95
7.1 Overview 95
7.2 Promising Drugs in Clinical Development 96
7.2.1 Cyramza (Ramucirumab) 97
7.2.2 Imprime PGG 102
7.2.3 MGN1703 107
7.2.4 Nintedanib (BIBF-1120) 112
7.3 Promising Approaches in Early-Stage Development 116
7.3.1 Anti-Angiopoietin-2 Inhibitors 116
7.3.2 Strategies for BRAF Mutation-Positive Disease 119
7.3.3 Strategies for KRAS-Mutation Positive Disease 125
7.3.4 Immune Checkpoint Inhibitors 128
8 Market Outlook 133
8.1 Drivers and Barriers - Global Issues 133
8.1.1 Driver: Increasing Worldwide Population Age 133
8.1.2 Driver: Launch of Premium-Priced Adjuvant/Maintenance Therapies 133
8.1.3 Driver: Launch of Premium-Priced Products for Later-Line Therapy 134
8.1.4 Barrier: Lack of Development of Neoadjuvant or Adjuvant Pipeline Agents 134
8.1.5 Barrier: Patent Expiration of Avastin 135
8.1.6 Barrier: Increasing Cost-Consciousness 135
8.2 France 136
8.2.1 Forecast 136
8.2.2 Key Events 140
8.2.3 Drivers and Barriers 140
8.3 Germany 143
8.3.1 Forecast 143
8.3.2 Key Events 147
8.3.3 Drivers and Barriers 147
8.4 Italy 149
8.4.1 Forecast 149
8.4.2 Key Events 153
8.4.3 Drivers and Barriers 153
8.5 Spain 155
8.5.1 Forecast 155
8.5.2 Key Events 159
8.5.3 Drivers and Barriers 159
8.6 United Kingdom 161
8.6.1 Forecast 161
8.6.2 Key Events 165
8.6.3 Drivers and Barriers 165
9 Appendix 168
9.1 Bibliography 168
9.2 Abbreviations 190
9.3 Methodology 196
9.4 Forecasting Methodology 196
9.4.1 Diagnosed Colorectal Cancer Patients 196
9.4.2 Percent Drug-Treated Patients 197
9.4.3 Drugs Included in Each Therapeutic Class 197
9.4.4 Launch and Patent Expiration Dates 197
9.4.5 General Pricing Assumptions 198
9.4.6 Average Body Weight and Surface Area 199
9.4.7 Individual Drug Assumptions 199
9.4.8 Generic Erosion 204
9.4.9 Pricing of Pipeline Agents 204
9.5 Primary Research - KOLs Interviewed for this Report 205
9.6 Primary Research - Prescriber Survey 206
9.7 About the Authors 207
9.7.1 Analyst 207
9.7.2 Global Head of Healthcare 208
9.8 About GlobalData 209
9.9 Disclaimer 209

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 20
Table 2: Symptoms of Colorectal Cancer 21
Table 3: Treatment Guidelines for CRC 26
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 27
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 28
Table 6: Country Profile - France 35
Table 7: Country Profile - Germany 39
Table 8: Country Profile - Italy 43
Table 9: Country Profile - Spain 47
Table 10: Country Profile - UK 51
Table 11: Leading Treatments for CRC, 2014 56
Table 12: Product Profile — Avastin 58
Table 13: Avastin SWOT Analysis, 2014 60
Table 14: Product Profile — Erbitux 62
Table 15: Erbitux SWOT Analysis, 2014 64
Table 16: Product Profile - Vectibix 66
Table 17: Vectibix SWOT Analysis, 2014 68
Table 18: Product Profile - Stivarga 70
Table 19: Stivarga SWOT Analysis, 2014 72
Table 20: Product Profile - Zaltrap 74
Table 21: Zaltrap SWOT Analysis, 2014 75
Table 22: Product Profile - Lonsurf 78
Table 23: Lonsurf SWOT Analysis, 2014 80
Table 24: Product Profile - Xeloda 81
Table 25: Unmet Need and Opportunity in CRC 85
Table 26: Product Profile - Cyramza 100
Table 27: Cyramza SWOT Analysis, 2014 102
Table 28: Product Profile - Imprime PGG 104
Table 29: Imprime PGG SWOT Analysis, 2014 107
Table 30: Product Profile - MGN1703 109
Table 31: MGN1703 SWOT Analysis, 2014 112
Table 32: Product Profile - Nintedanib 114
Table 33: Nintedanib SWOT Analysis, 2014 116
Table 34: Anti-Angiopoietin-2 Inhibitors in Development 117
Table 35: Early-stage Strategies for BRAF Mutation-Positive CRC 120
Table 36: Early-stage Strategies for KRAS Mutation-Positive CRC 126
Table 37: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC 130
Table 38: CRC Market Drivers and Barriers, 2014 133
Table 39: Sales Forecasts ($m) for Colorectal Cancer in France, 2013-2023 138
Table 40: Key Events Impacting Sales for CRC in France, 2014 140
Table 41: France CRC Market Drivers and Barriers, 2014 140
Table 42: Sales Forecasts ($m) for Colorectal Cancer in Germany, 2013-2023 145
Table 43: Key Events Impacting Sales for CRC in Germany, 2014 147
Table 44: Germany CRC Market Drivers and Barriers, 2014 147
Table 45: Sales Forecasts ($m) for Colorectal Cancer in Italy, 2013-2023 151
Table 46: Key Events Impacting Sales for CRC in Italy, 2014 153
Table 47: Italy CRC Market Drivers and Barriers, 2014 153
Table 48: Sales Forecasts ($m) for Colorectal Cancer in Spain, 2013-2023 157
Table 49: Key Events Impacting Sales for CRC in Spain, 2014 159
Table 50: Spain CRC Market Drivers and Barriers, 2014 159
Table 51: Sales Forecasts ($m) for Colorectal Cancer in the UK, 2013-2023 163
Table 52: Key Events Impacting Sales for CRC in the UK, 2014 165
Table 53: UK CRC Market - Drivers and Barriers, 2014 165
Table 54: Key Launch Dates 197
Table 55: Key Patent Expiries 198
Table 56: Average Body Weight and Surface Area 199
Table 57: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 206

1.2 List of Figures
Figure 1: CRC - Phase III Pipeline 96
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023 97
Figure 3: Clinical and Commercial Positioning of Cyramza 101
Figure 4: Clinical and Commercial Positioning of Imprime PGG 106
Figure 5: Clinical and Commercial Positioning of MGN1703 111
Figure 6: Clinical and Commercial Positioning of Nintedanib 115
Figure 7: Sales for Colorectal Cancer in France by Drug Class, 2013-2023 139
Figure 8: Sales for Colorectal Cancer in Germany by Drug Class, 2013-2023 146
Figure 9: Sales for Colorectal Cancer in Italy by Drug Class, 2013-2023 152
Figure 10: Sales for Colorectal Cancer in Spain by Drug Class, 2013-2023 158
Figure 11: Sales for Colorectal Cancer in the United Kingdom by Drug Class, 2013-2023 164

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer: Analytical Tool

Colorectal Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Colorectal cancer (mCRC)- Market Insights, Epidemiology and Market Forecast-2023

Colorectal cancer (mCRC)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Colorectal cancer (mCRC - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Global Colorectal Cancer Screening Tests Market - Industry Analysis and Market Forecast (2016 - 2021)

Global Colorectal Cancer Screening Tests Market - Industry Analysis and Market Forecast (2016 - 2021)

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

US Colorectal Cancer Screening Tests Rate to Rise Up to 80% by 2018 The American Cancer Society reports Colon Cancer diagnosis rate has dropped 30% in the US in the last 10 years for those aged 50 years ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.